Stockreport

Stemline Therapeutics Announces Three ELZONRIS™ (tagraxofusp; SL-401) Clinical Presentations, Including an Oral Presentation, at the EHA Congress

STEMLINE THERAPEUTICS  (STML) 
Last stemline therapeutics earnings: 3/13 04:45 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.stemline.com/investor-relations
PDF NEW YORK, June 14, 2018 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel oncology therapeutic [Read more]